A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

NCT07716618 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: SAL0120 1mg
DRUG: SAL0120 2mg
DRUG: SAL0120 4mg
DRUG: Placebo

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Collaborators

[object Object]